PetMed Express Announces $1.2 Million Trade Name Impairment

An announcement from Petmed Express ( (PETS) ) is now available.

On October 1, 2025, PetMed Express announced a $1.2 million non-cash impairment of its PCRX trade name for the quarter ended March 31, 2025, due to reduced actual and forecasted revenues. This impairment does not require future cash expenditures but highlights potential financial challenges, as the company also faces a sustained decline in its stock price, which may indicate further goodwill impairments affecting its financial condition and capital access.

The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.

Spark’s Take on PETS Stock

According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.

Petmed Express shows a mixed financial performance with strong balance sheet stability but weak profitability and inconsistent cash flow. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics suggest the stock may be overvalued. The earnings call highlights progress in profitability and strategic investments, but challenges remain in sales and competitive pressures. Overall, the stock score reflects these combined factors, indicating moderate potential with significant risks.

To see Spark’s full report on PETS stock, click here.

More about Petmed Express

PetMed Express, Inc. operates in the pet pharmaceutical industry, focusing on providing prescription and non-prescription pet medications and other health products for pets. The company acquired PetCareRx in April 2023, which expanded its portfolio of intangible assets, including the PCRX trade name.

Average Trading Volume: 135,230

Technical Sentiment Signal: Sell

Current Market Cap: $52.67M

See more data about PETS stock on TipRanks’ Stock Analysis page.